Skip to content
TrialMatch
Sign up
Recruiting

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.

Condition
Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer, Squamous Cell Carcinoma of Head and Neck, Small Cell Carcinoma, NSCLC
Tested
MDSC quantification
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Who can join

Age
18 to 90 years
Sex
All sexes
Healthy volunteers
Accepted

Inclusion 10

  • Minimum age: 18 years
  • Maximum age: 90 years
  • Study condition: Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer, Squamous Cell Carcinoma of Head and Neck, Small Cell Carcinoma, NSCLC
  • Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included
  • Will and ability to comply with the protocol
  • Willingness and ability to provide an adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample available for exploratory biomarker analysis
  • Age from 18 to 90 years at the time of recruitment
  • ECOG Performance Status \<= 2
  • Understanding and signature of the informed consent
  • Consenting to participate to the socio-economical-psychological survey

Exclusion 5

  • Known history of HIV infection
  • Serious neurological or psychiatric disorders
  • Pregnancy or lactation
  • Inability or unwillingness of participant to give written informed consent
  • Inability or unwillingness to be regularly followed up at the same center

Where

1 site, 1 recruiting

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.